Compugen (XTAE:CGEN) Notes Receivable: ₪0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:CGEN Compugen Ltd XTAE:CGEN
43 GF Score
Price ₪7.62
! 4 Warning Signs
View Full Analysis

What is Compugen Notes Receivable?

Compugen XTAE:CGEN +5.24% 43 Notes Receivable is ₪0.0 Mil as of Mar. 2026. GuruFocus rates XTAE:CGEN with a GF Score™ of 43/100. The stock has 4 warning signs investors should review.

Compugen's Notes Receivable for the quarter that ended in Mar. 2026 was ₪0.0 Mil.

Compugen Notes Receivable Historical Data

* Premium members only.

The historical data trend for Compugen's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compugen Notes Receivable Chart

Compugen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Compugen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XTAE:CGEN
43GF Score
Compugen Ltd XTAE:CGEN
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compugen Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₪0.0 Mil mean?
Compugen (XTAE:CGEN) has a Notes Receivable of ₪0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Compugen and its competitors.
Is Compugen's Notes Receivable too high?
Compugen's current Notes Receivable is ₪0.0 Mil. Overall, Compugen has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Compugen's Notes Receivable compare to VRTX and REGN?
Compugen's Notes Receivable of ₪0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Compugen and its competitors. Compugen's current Notes Receivable is ₪0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compugen stock overvalued right now?
Compugen (XTAE:CGEN) has a current Notes Receivable of ₪0.0 Mil. The current Notes Receivable is ₪0.0 Mil. Compugen's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Compugen (XTAE:CGEN), the current Notes Receivable is ₪0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Compugen Business Description

Other Exchanges CGEN:USA
Address 26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
43GF Score

Get the complete analysis for XTAE:CGEN

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪7.62
Price